Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction

• 作者: Wenyu Fu Yujianan Chen Kaidi Wang Aubryanna Hettinghouse Wenhuo Hu Jing-Quan Wang Zi-Ning Lei Zhe-Sheng Chen Kenneth A.Stapleford Chuan-ju Liu
• 来源期刊: 蛋白质与细胞
• 年，卷（期）: 2021,（7）
• 所属期刊栏目: LETTERS
• 页码范围: 586-591
• 页数: 6页
• 语种: 英文

摘要

Dear Editor, The ongoing coronavirus disease 2019(COVID-19)global pandemic is caused by a novel coronavirus,severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),which instigates severe and often fatal symptoms.As of September 4th,2020,more than 26 million cases of COVID-19 and almost 900,000 deaths have been reported to WHO.Based on Kissler and colleagues'modeled projections of future viral transmission scenarios,a resurgence in SARS-CoV-2 could occur over the next five years(Kissler et al.,2020).Research and clinical trials are underway to develop vacci-nes and treatments for COVID-19,but there are currently no specific vaccines or treatments for COVID-19(www.who.int),and therapeutic and prophylactic interventions are urgently needed to combat the outbreak of SARS-CoV-2.Of partic-ular importance is the identification of drugs which are effective,less-intrusive,most socioeconomic,and ready-to-use.